All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Listed as ongoing, but also has a completion date and reported results | 2015-005758-36 | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chroni... | 2023-03-29 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-004339-19 | A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304 | 2022-07-11 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-004718-90 | A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgk... | 2022-07-04 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-000638-75 | Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY) | 2020-11-06 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-000639-15 | Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY) | 2020-11-12 | bad-data |
| Other | 2019-003625-16 | An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | not-yet-due |